TVRD

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for Cara Therapeutics, Inc. (Ticker: CARA) for the fiscal year ended December 31, 2024. The company is a biopharmaceutical firm focused on chronic pruritus, primarily through its product KORSUVA (difelikefalin). In 2024, Cara discontinued its clinical program for oral difelikefalin in notalgia paresthetica (NP) following negative trial results. Consequently, the Board approved a streamlined operating plan and a proposed merger with Tvardi Therapeutics, Inc., which, if consummated, will rename the combined entity "Tvardi Therapeutics, Inc." and trade under the symbol "TVRD."

Key Financial Metrics

Note: The filing text does not provide a specific "profit margin" as the company is unprofitable. Revenue declined 66% year-over-year primarily due to the expiration of favorable CMS reimbursement rules for KORSUVA.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue dropped 66% to $7.1 million. Collaborative revenue from KORSUVA fell 84% to $2.1 million due to negative net sales reported by partner CSL Vifor in Q2 and Q4 2024, driven by higher rebates and chargebacks following the expiration of the Transition Drug Add-on Payment Adjustment (TDAPA).
• Expense Reductions: Research and Development (R&D) expenses decreased 70% to $32.8 million following the discontinuation of the NP clinical program and workforce reductions. General and Administrative (G&A) expenses remained relatively flat at $26.5 million.
• One-Time Charges: The company recorded $5.6 million in restructuring expenses, a $4.3 million impairment of long-lived assets (related to the assignment of its corporate lease), and a $3.0 million inventory write-down.
• Equity Position: Stockholders' equity turned negative to $(4.6) million, primarily due to the accumulated deficit and asset impairments.

Guidance, Outlook, and Risks

• Merger with Tvardi: The primary strategic focus is the proposed merger with Tvardi Therapeutics, Inc. The transaction is subject to stockholder approval and other conditions. If completed, Cara's pre-merger equity holders are expected to own approximately 15.25% of the combined company.
• Asset Disposition: Concurrent with the merger, Cara plans to sell its difelikefalin assets and rights to CSL Vifor for $0.9 million (subject to adjustments), while agreeing to pay CSL Vifor $3.0 million for incremental future expenses.
• Liquidity: Management expects current cash and cash equivalents ($37.9 million) to fund operations for at least the next 12 months. However, if the merger fails, the company may pursue dissolution and liquidation.
• Nasdaq Compliance: Cara regained compliance with the minimum bid price requirement ($1.00) via a 1-for-12 reverse stock split in December 2024. However, it remains non-compliant with the Stockholders' Equity Requirement ($2.5 million minimum) and has received an extension until May 19, 2025, to regain compliance, contingent on the merger closing.
• Risks: Key risks include the failure to consummate the merger, potential delisting from Nasdaq if equity requirements are not met, and the uncertainty of future funding if the merger does not close.

Investor Verification Checklist

• Merger Approval: Verify the status of stockholder votes for both Cara and Tvardi required to close the merger.
• Nasdaq Status: Monitor whether the company meets the Stockholders' Equity Requirement by the May 19, 2025 deadline to avoid delisting.
• Asset Sale Terms: Confirm the final terms of the Asset Disposition with CSL Vifor, specifically the $3.0 million payment obligation and the $0.9 million purchase price.
• Liquidity Runway: Assess the burn rate and cash position if the merger is delayed or terminated, as the company has no other committed funding sources.
• Ownership Dilution: Review the final exchange ratio and post-merger ownership structure, noting that existing Cara shareholders will hold a minority stake (~15%) in the combined entity.